<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62081">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917136</url>
  </required_header>
  <id_info>
    <org_study_id>817786</org_study_id>
    <nct_id>NCT01917136</nct_id>
  </id_info>
  <brief_title>11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension</brief_title>
  <official_title>Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular Medical Research and Education Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at differences in metabolism and functional imaging between pulmonary
      hypertension subjects with near normal right ventricular function and persistent right
      ventricular dysfunction. We will also measure right ventricular metabolic and structural
      changes using serial 11C-acetate and 18F-FDG PET/CT and cardiac MRI as response to treatment
      with ranolazine. Subjects undergo imaging procedures at week 0 and week 26 (optional for
      near normal function patients). This is a companion imaging trial for patients who are
      eligible for the treatment trial entitled &quot;A randomized, double-blind, placebo controlled,
      multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary
      hypertension and right ventricular dysfunction accompanied by a comparative study of
      cellular metabolism in subjects with pulmonary hypertension with and without right
      ventricular dysfunction&quot;.  Subjects must enroll in companion treatment protocol to qualify
      for the imaging protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Myocardial oxygen consumption, FDG uptake, and myocardial perfusion</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare Myocardial oxygen consumption, FDG uptake, and myocardial perfusion at baseline for subjects with near normal right ventricular function and those with persistent right ventricular dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial oxygen consumption and FDG uptake and myocardial perfusion</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess change from baseline in Myocardial oxygen consumption and FDG uptake and myocardial perfusion in subjects with persistent right ventricular dysfunction who are treated with ranolazine or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in myocardial structure and function</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using CMR, comparing myocardial structure and function in patients treated with ranolazine or placebo</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>11c-acetate and 18F-FDG, and cardiac MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-acetate</intervention_name>
    <description>For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate</description>
    <arm_group_label>11c-acetate and 18F-FDG, and cardiac MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]Fluoro-2-deoxy-2-D-glucose</intervention_name>
    <description>For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG</description>
    <arm_group_label>11c-acetate and 18F-FDG, and cardiac MRI</arm_group_label>
    <other_name>18F-FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Cardiac MRI is performed at 6 months to measure any change in struction and function of the treatment groups.</description>
    <arm_group_label>11c-acetate and 18F-FDG, and cardiac MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participation in the companion treatment protocol &quot;A randomized, double-blind, placebo
        controlled, multi-center study to assess the effect of ranolazine on outcomes in subjects
        with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative
        study of cellular metabolism in subjects with pulmonary hypertension with and without
        right ventricular dysfunction&quot;

        Exclusion Criteria:

          -  Pregnancy or lactation: Women of childbearing potential must have a negative urine or
             blood pregnancy test on the day of the PET/CT scan.

          -  Anxiety or claustrophobia prohibiting completion of imaging

          -  Inability to tolerate imaging procedures (1 hour MRI, 30 min and 15 min PET)

          -  Moderate to severe chronic renal disease defined as an estimated glomerular
             filtration rate &lt; 30 ml/min/1.73m2

          -  Implantable cardioverter-defibrillator, Pacemaker, hazardous metallic implants or any
             other contraindication to MRI.

          -  History of uncontrolled diabetes mellitus with fasting glucose &gt; 150 mg/dL at the
             treatment protocol screening visit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuchi Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuchi Han, MD</last_name>
    <phone>215-662-2855</phone>
    <email>yuchi.han@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Baer, MB, MBA</last_name>
    <email>baer2@mail.med.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuchi Han, MD</last_name>
      <email>yuchi.han@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Baer, MB, MBA</last_name>
      <email>baer2@mail.med.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>August 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Yuchi Han</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <keyword>right ventricular function</keyword>
  <keyword>11C acetate</keyword>
  <keyword>FDG</keyword>
  <keyword>ranolazine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
